Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer
Researchers conducted the QUADRA trial to examine if niraparib could improve outcomes in heavily pretreated patients with ovarian cancer.
Seven-Year Follow-Up Results Can Help HER2+ Breast Cancer Patients Avoid Overtreatment
The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.
Using Telerehabilitation to Improve Function and Pain in Advanced Cancer Patients
Telerehabilitation and pharmacological pain management approaches were tested in patients with advanced cancers, including prostate cancer, to see if pain and function could be improved.
Should Adjuvant Chemo Be Added to Treatment in Early High-Risk Prostate Cancer?
Researchers tested the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in patients with localized high-risk prostate cancer.
On the TRAIL of a Solution to Trastuzumab Resistance in HER2+ Breast Cancer
A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.
Are Assessment Guidelines for HER2 Status Leading to Many False Positives?
Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.
Umbralisib Offers Promise for Marginal Zone Lymphoma
Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.
Adding an Oncolytic Virus to Neoadjuvant Chemo for Triple-Negative Breast Cancer
A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Pembrolizumab Offers New Option in Extensive-Stage Lung Cancer
A pooled analysis of two trials presented at the AACR Annual Meeting looked at the use of pembrolizumab in patients with heavily pretreated extensive small-cell lung cancer.
Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.
What Role Does Systemic Inflammation Play in Triple-Negative Breast Cancer?
Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.
Racial Disparities in Hospice Enrollment Persist in Ovarian Cancer
In this study, researchers aimed to further characterize differences in hospice use in a cohort of ovarian cancer patients.
Lymphadenectomy in Advanced Ovarian Cancer: Will It Improve Survival?
A randomized trial tested whether lymphadenectomy would improve survival outcomes in patients with advanced ovarian cancer.
Studying the Effects of Low-Dose Aspirin on Prostate Cancer Outcomes
A large Danish registry study looked at the effects of post-diagnosis use of low-dose aspirin on prostate cancer mortality.
Adding Docetaxel to ADT for High-Risk Nonmetastatic Prostate Cancer: Does It Help?
Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer.
Tumor Mutational Burden to Guide Immunotherapy in Lung Cancer
A trial showed that tumor mutational burden may be effective as a biomarker in patients treated with immunotherapy.
FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.
Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?
Researchers studied the combination of a cellular vaccine known as HS-110 and nivolumab in an early-phase trial of patients with advanced non–small-cell lung cancer.
Adding Checkpoint Inhibition in Trastuzumab-Resistant HER2+ Breast Cancer
An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1–positive, trastuzumab-resistant, advanced HER2+ breast cancer.
Which Breast Cancer Risk Models Are Most Accurate?
Researchers conducted a validation study of four breast cancer risk models currently in use.
Denosumab Plus AI Therapy Can Improve Outcomes in HR+ Breast Cancer
The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer.
Large Study Sheds Light on Risks for Second Cancers Among Young Survivors
Researchers investigated the risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer.
How Could Machine Learning and Radiomics Improve Ovarian Cancer Care?
A score derived from CT imaging using a machine learning radiomics approach was able to reliably identify epithelial ovarian cancer patients with poor survival outcomes.
Could Conservative Management of Adnexal Masses Lead to Ovarian Cancer?
Researchers tested whether conservative management of adnexal masses classified as benign could lead to subsequent malignant ovarian cancer.
Intervention Illustrates Ways to Reduce Racial Disparities in Lung Cancer Care
A set of simple interventions succeeded in reducing disparities in lung cancer care between black and white patients across five cancer centers.
Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.
Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?
The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.
Precision Medicine Umbrella Trial Expands to Include All NSCLC Patients
The large precision medicine trial known as Lung-MAP has announced it will expand to patients with all non–small-cell lung cancers, accounting for as many as 85% of all lung cancer diagnoses in the US.
Hypofractionated Radiotherapy Offers an Alternative in High-Risk Breast Cancer
Researchers compared hypofractionated radiotherapy vs a conventional regimen to study outcomes and toxicity in breast cancer patients.
Concerning Rate of Complications Found Following Immediate Breast Reconstruction
Researchers conducted a study to evaluate the short-term clinical outcomes of varying approaches to immediate implant-based breast reconstruction in the UK.